nodes	percent_of_prediction	percent_of_DWPC	metapath
Dasatinib—CYP1B1—Estradiol—osteoporosis	0.0568	0.163	CbGbCtD
Dasatinib—CYP1A1—Cholecalciferol—osteoporosis	0.0309	0.0885	CbGbCtD
Dasatinib—ABCG2—Conjugated Estrogens—osteoporosis	0.0308	0.088	CbGbCtD
Dasatinib—ABCG2—Estradiol—osteoporosis	0.027	0.0773	CbGbCtD
Dasatinib—CYP1A2—Estropipate—osteoporosis	0.0268	0.0767	CbGbCtD
Dasatinib—CYP1A1—Estradiol—osteoporosis	0.0249	0.0713	CbGbCtD
Dasatinib—ABCB1—Ethinyl Estradiol—osteoporosis	0.0151	0.0432	CbGbCtD
Dasatinib—CYP3A5—Estradiol—osteoporosis	0.015	0.0428	CbGbCtD
Dasatinib—CYP3A4—Estropipate—osteoporosis	0.0141	0.0402	CbGbCtD
Dasatinib—CYP3A4—Calcitriol—osteoporosis	0.0141	0.0402	CbGbCtD
Dasatinib—CYP1A2—Conjugated Estrogens—osteoporosis	0.0127	0.0363	CbGbCtD
Dasatinib—CYP3A4—Ergocalciferol—osteoporosis	0.0112	0.0321	CbGbCtD
Dasatinib—CYP1A2—Estradiol—osteoporosis	0.0111	0.0319	CbGbCtD
Dasatinib—ABCB1—Conjugated Estrogens—osteoporosis	0.0111	0.0317	CbGbCtD
Dasatinib—ABCB1—Estradiol—osteoporosis	0.00974	0.0279	CbGbCtD
Dasatinib—CYP3A4—Raloxifene—osteoporosis	0.00938	0.0268	CbGbCtD
Dasatinib—CYP3A4—Ethinyl Estradiol—osteoporosis	0.00906	0.0259	CbGbCtD
Dasatinib—CYP3A4—Cholecalciferol—osteoporosis	0.00724	0.0207	CbGbCtD
Dasatinib—CYP3A4—Conjugated Estrogens—osteoporosis	0.00665	0.019	CbGbCtD
Dasatinib—SRC—periosteum—osteoporosis	0.00589	0.0885	CbGeAlD
Dasatinib—CYP3A4—Estradiol—osteoporosis	0.00584	0.0167	CbGbCtD
Dasatinib—CSF1R—periosteum—osteoporosis	0.00529	0.0794	CbGeAlD
Dasatinib—BMX—uterus—osteoporosis	0.00201	0.0302	CbGeAlD
Dasatinib—SRMS—uterus—osteoporosis	0.00193	0.0289	CbGeAlD
Dasatinib—STAT5B—uterus—osteoporosis	0.00178	0.0268	CbGeAlD
Dasatinib—PKMYT1—bone marrow—osteoporosis	0.00175	0.0263	CbGeAlD
Dasatinib—BMX—bone marrow—osteoporosis	0.00171	0.0257	CbGeAlD
Dasatinib—SRMS—bone marrow—osteoporosis	0.00164	0.0246	CbGeAlD
Dasatinib—TXK—bone marrow—osteoporosis	0.00162	0.0243	CbGeAlD
Dasatinib—SIK3—uterus—osteoporosis	0.0016	0.0241	CbGeAlD
Dasatinib—STAT5B—bone marrow—osteoporosis	0.00151	0.0227	CbGeAlD
Dasatinib—ZAK—uterus—osteoporosis	0.00149	0.0224	CbGeAlD
Dasatinib—BMPR1B—uterus—osteoporosis	0.00143	0.0215	CbGeAlD
Dasatinib—TNK2—uterus—osteoporosis	0.0014	0.0211	CbGeAlD
Dasatinib—EPHB3—uterus—osteoporosis	0.0013	0.0195	CbGeAlD
Dasatinib—PKMYT1—Fulvestrant—Estradiol—osteoporosis	0.00126	0.259	CbGdCrCtD
Dasatinib—LIMK2—uterus—osteoporosis	0.00125	0.0188	CbGeAlD
Dasatinib—CSK—uterus—osteoporosis	0.00121	0.0181	CbGeAlD
Dasatinib—BTK—bone marrow—osteoporosis	0.00121	0.0181	CbGeAlD
Dasatinib—HCK—uterus—osteoporosis	0.00119	0.0179	CbGeAlD
Dasatinib—TESK1—Estradiol—Estropipate—osteoporosis	0.00111	0.229	CbGdCrCtD
Dasatinib—SIK1—uterus—osteoporosis	0.0011	0.0164	CbGeAlD
Dasatinib—EPHA4—uterus—osteoporosis	0.00108	0.0163	CbGeAlD
Dasatinib—ERBB3—uterus—osteoporosis	0.00107	0.0161	CbGeAlD
Dasatinib—MAP3K2—uterus—osteoporosis	0.00106	0.016	CbGeAlD
Dasatinib—CSK—bone marrow—osteoporosis	0.00103	0.0154	CbGeAlD
Dasatinib—HCK—bone marrow—osteoporosis	0.00101	0.0152	CbGeAlD
Dasatinib—MAPK14—uterus—osteoporosis	0.000999	0.015	CbGeAlD
Dasatinib—LCK—uterus—osteoporosis	0.000995	0.0149	CbGeAlD
Dasatinib—RIPK2—bone marrow—osteoporosis	0.000952	0.0143	CbGeAlD
Dasatinib—EPHB4—uterus—osteoporosis	0.000948	0.0142	CbGeAlD
Dasatinib—SIK1—bone marrow—osteoporosis	0.000929	0.014	CbGeAlD
Dasatinib—FYN—uterus—osteoporosis	0.000928	0.0139	CbGeAlD
Dasatinib—MAP4K5—uterus—osteoporosis	0.000907	0.0136	CbGeAlD
Dasatinib—MAP3K2—bone marrow—osteoporosis	0.000902	0.0135	CbGeAlD
Dasatinib—MAPK14—bone marrow—osteoporosis	0.000848	0.0127	CbGeAlD
Dasatinib—FGR—bone marrow—osteoporosis	0.000845	0.0127	CbGeAlD
Dasatinib—LCK—bone marrow—osteoporosis	0.000845	0.0127	CbGeAlD
Dasatinib—TESK1—Estradiol—Conjugated Estrogens—osteoporosis	0.000839	0.173	CbGdCrCtD
Dasatinib—YES1—uterus—osteoporosis	0.000837	0.0126	CbGeAlD
Dasatinib—PDGFRA—uterus—osteoporosis	0.000822	0.0123	CbGeAlD
Dasatinib—EPHB4—bone marrow—osteoporosis	0.000804	0.0121	CbGeAlD
Dasatinib—JAK2—bone marrow—osteoporosis	0.000798	0.012	CbGeAlD
Dasatinib—FYN—bone marrow—osteoporosis	0.000788	0.0118	CbGeAlD
Dasatinib—MAP4K5—bone marrow—osteoporosis	0.00077	0.0116	CbGeAlD
Dasatinib—MAP3K3—bone marrow—osteoporosis	0.00077	0.0116	CbGeAlD
Dasatinib—CSF1R—uterus—osteoporosis	0.000723	0.0109	CbGeAlD
Dasatinib—YES1—bone marrow—osteoporosis	0.000711	0.0107	CbGeAlD
Dasatinib—TESK1—Estradiol—Ethinyl Estradiol—osteoporosis	0.000705	0.146	CbGdCrCtD
Dasatinib—KIT—uterus—osteoporosis	0.000657	0.00986	CbGeAlD
Dasatinib—PDGFRB—uterus—osteoporosis	0.000641	0.00963	CbGeAlD
Dasatinib—CSF1R—bone marrow—osteoporosis	0.000614	0.00922	CbGeAlD
Dasatinib—ABL1—uterus—osteoporosis	0.000572	0.00859	CbGeAlD
Dasatinib—KIT—bone marrow—osteoporosis	0.000557	0.00837	CbGeAlD
Dasatinib—PKMYT1—Danazol—Ethinyl Estradiol—osteoporosis	0.000548	0.113	CbGdCrCtD
Dasatinib—PDGFRB—bone marrow—osteoporosis	0.000544	0.00818	CbGeAlD
Dasatinib—ABL1—bone marrow—osteoporosis	0.000485	0.00729	CbGeAlD
Dasatinib—CYP1B1—uterus—osteoporosis	0.000484	0.00727	CbGeAlD
Dasatinib—ABL1—Levorphanol—Estradiol—osteoporosis	0.000387	0.0798	CbGdCrCtD
Dasatinib—ABCG2—uterus—osteoporosis	0.000361	0.00541	CbGeAlD
Dasatinib—CYP1A1—uterus—osteoporosis	0.000342	0.00514	CbGeAlD
Dasatinib—ABCG2—bone marrow—osteoporosis	0.000306	0.0046	CbGeAlD
Dasatinib—ABCB1—uterus—osteoporosis	0.000178	0.00267	CbGeAlD
Dasatinib—Anxiety—Zoledronate—osteoporosis	0.000151	0.000517	CcSEcCtD
Dasatinib—ABCB1—bone marrow—osteoporosis	0.000151	0.00227	CbGeAlD
Dasatinib—Loss of consciousness—Conjugated Estrogens—osteoporosis	0.000151	0.000515	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.000151	0.000515	CcSEcCtD
Dasatinib—Pruritus—Estropipate—osteoporosis	0.00015	0.000512	CcSEcCtD
Dasatinib—Discomfort—Zoledronate—osteoporosis	0.00015	0.000512	CcSEcCtD
Dasatinib—Asthenia—Alendronate—osteoporosis	0.00015	0.000512	CcSEcCtD
Dasatinib—Hypersensitivity—Ibandronate—osteoporosis	0.00015	0.000512	CcSEcCtD
Dasatinib—Cough—Conjugated Estrogens—osteoporosis	0.00015	0.000512	CcSEcCtD
Dasatinib—Dyspnoea—Risedronate—osteoporosis	0.000149	0.00051	CcSEcCtD
Dasatinib—Erythema multiforme—Estradiol—osteoporosis	0.000149	0.00051	CcSEcCtD
Dasatinib—Hypotension—Pamidronate—osteoporosis	0.000149	0.000508	CcSEcCtD
Dasatinib—Convulsion—Conjugated Estrogens—osteoporosis	0.000149	0.000508	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.000148	0.000507	CcSEcCtD
Dasatinib—Fatigue—Ethinyl Estradiol—osteoporosis	0.000148	0.000506	CcSEcCtD
Dasatinib—Pruritus—Alendronate—osteoporosis	0.000148	0.000505	CcSEcCtD
Dasatinib—Dyspepsia—Risedronate—osteoporosis	0.000147	0.000504	CcSEcCtD
Dasatinib—Eye disorder—Estradiol—osteoporosis	0.000147	0.000504	CcSEcCtD
Dasatinib—Tinnitus—Estradiol—osteoporosis	0.000147	0.000503	CcSEcCtD
Dasatinib—Constipation—Ethinyl Estradiol—osteoporosis	0.000147	0.000502	CcSEcCtD
Dasatinib—Confusional state—Zoledronate—osteoporosis	0.000147	0.000501	CcSEcCtD
Dasatinib—Hypersensitivity—Calcitriol—osteoporosis	0.000147	0.000501	CcSEcCtD
Dasatinib—Flushing—Estradiol—osteoporosis	0.000146	0.0005	CcSEcCtD
Dasatinib—Cardiac disorder—Estradiol—osteoporosis	0.000146	0.0005	CcSEcCtD
Dasatinib—Chest pain—Conjugated Estrogens—osteoporosis	0.000146	0.000499	CcSEcCtD
Dasatinib—Arthralgia—Conjugated Estrogens—osteoporosis	0.000146	0.000499	CcSEcCtD
Dasatinib—Myalgia—Conjugated Estrogens—osteoporosis	0.000146	0.000499	CcSEcCtD
Dasatinib—Asthenia—Ibandronate—osteoporosis	0.000146	0.000498	CcSEcCtD
Dasatinib—Anxiety—Conjugated Estrogens—osteoporosis	0.000146	0.000497	CcSEcCtD
Dasatinib—Nausea—Etidronic acid—osteoporosis	0.000146	0.000497	CcSEcCtD
Dasatinib—Oedema—Zoledronate—osteoporosis	0.000145	0.000497	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.000145	0.000496	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Pamidronate—osteoporosis	0.000145	0.000496	CcSEcCtD
Dasatinib—Diarrhoea—Estropipate—osteoporosis	0.000145	0.000496	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Risedronate—osteoporosis	0.000145	0.000494	CcSEcCtD
Dasatinib—Infection—Zoledronate—osteoporosis	0.000144	0.000494	CcSEcCtD
Dasatinib—Fatigue—Risedronate—osteoporosis	0.000144	0.000493	CcSEcCtD
Dasatinib—Insomnia—Pamidronate—osteoporosis	0.000144	0.000492	CcSEcCtD
Dasatinib—Pruritus—Ibandronate—osteoporosis	0.000144	0.000491	CcSEcCtD
Dasatinib—Pain—Risedronate—osteoporosis	0.000143	0.000489	CcSEcCtD
Dasatinib—Constipation—Risedronate—osteoporosis	0.000143	0.000489	CcSEcCtD
Dasatinib—Angiopathy—Estradiol—osteoporosis	0.000143	0.000489	CcSEcCtD
Dasatinib—Shock—Zoledronate—osteoporosis	0.000143	0.000489	CcSEcCtD
Dasatinib—Diarrhoea—Alendronate—osteoporosis	0.000143	0.000488	CcSEcCtD
Dasatinib—Asthenia—Calcitriol—osteoporosis	0.000143	0.000488	CcSEcCtD
Dasatinib—Nervous system disorder—Zoledronate—osteoporosis	0.000143	0.000487	CcSEcCtD
Dasatinib—Immune system disorder—Estradiol—osteoporosis	0.000142	0.000487	CcSEcCtD
Dasatinib—Thrombocytopenia—Zoledronate—osteoporosis	0.000142	0.000487	CcSEcCtD
Dasatinib—Mediastinal disorder—Estradiol—osteoporosis	0.000142	0.000486	CcSEcCtD
Dasatinib—Dyspnoea—Pamidronate—osteoporosis	0.000142	0.000485	CcSEcCtD
Dasatinib—Tachycardia—Zoledronate—osteoporosis	0.000142	0.000485	CcSEcCtD
Dasatinib—Feeling abnormal—Ethinyl Estradiol—osteoporosis	0.000142	0.000484	CcSEcCtD
Dasatinib—Chills—Estradiol—osteoporosis	0.000142	0.000484	CcSEcCtD
Dasatinib—Somnolence—Pamidronate—osteoporosis	0.000142	0.000484	CcSEcCtD
Dasatinib—Skin disorder—Zoledronate—osteoporosis	0.000141	0.000483	CcSEcCtD
Dasatinib—Pruritus—Calcitriol—osteoporosis	0.000141	0.000481	CcSEcCtD
Dasatinib—Hyperhidrosis—Zoledronate—osteoporosis	0.000141	0.00048	CcSEcCtD
Dasatinib—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	0.00014	0.00048	CcSEcCtD
Dasatinib—Diarrhoea—Raloxifene—osteoporosis	0.00014	0.00048	CcSEcCtD
Dasatinib—Dyspepsia—Pamidronate—osteoporosis	0.00014	0.000479	CcSEcCtD
Dasatinib—Dizziness—Estropipate—osteoporosis	0.00014	0.000479	CcSEcCtD
Dasatinib—Oedema—Conjugated Estrogens—osteoporosis	0.00014	0.000479	CcSEcCtD
Dasatinib—Alopecia—Estradiol—osteoporosis	0.000139	0.000476	CcSEcCtD
Dasatinib—Infection—Conjugated Estrogens—osteoporosis	0.000139	0.000475	CcSEcCtD
Dasatinib—Diarrhoea—Ibandronate—osteoporosis	0.000139	0.000475	CcSEcCtD
Dasatinib—Anorexia—Zoledronate—osteoporosis	0.000139	0.000474	CcSEcCtD
Dasatinib—Decreased appetite—Pamidronate—osteoporosis	0.000138	0.000473	CcSEcCtD
Dasatinib—Mental disorder—Estradiol—osteoporosis	0.000138	0.000472	CcSEcCtD
Dasatinib—Dizziness—Alendronate—osteoporosis	0.000138	0.000472	CcSEcCtD
Dasatinib—Shock—Conjugated Estrogens—osteoporosis	0.000138	0.000471	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000137	0.00047	CcSEcCtD
Dasatinib—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.000137	0.000469	CcSEcCtD
Dasatinib—Erythema—Estradiol—osteoporosis	0.000137	0.000469	CcSEcCtD
Dasatinib—Malnutrition—Estradiol—osteoporosis	0.000137	0.000469	CcSEcCtD
Dasatinib—Fatigue—Pamidronate—osteoporosis	0.000137	0.000469	CcSEcCtD
Dasatinib—Gastrointestinal pain—Risedronate—osteoporosis	0.000137	0.000468	CcSEcCtD
Dasatinib—Tachycardia—Conjugated Estrogens—osteoporosis	0.000137	0.000467	CcSEcCtD
Dasatinib—Urticaria—Ethinyl Estradiol—osteoporosis	0.000136	0.000466	CcSEcCtD
Dasatinib—Pain—Pamidronate—osteoporosis	0.000136	0.000465	CcSEcCtD
Dasatinib—Constipation—Pamidronate—osteoporosis	0.000136	0.000465	CcSEcCtD
Dasatinib—Diarrhoea—Calcitriol—osteoporosis	0.000136	0.000465	CcSEcCtD
Dasatinib—Skin disorder—Conjugated Estrogens—osteoporosis	0.000136	0.000465	CcSEcCtD
Dasatinib—Hypotension—Zoledronate—osteoporosis	0.000136	0.000464	CcSEcCtD
Dasatinib—Abdominal pain—Ethinyl Estradiol—osteoporosis	0.000136	0.000464	CcSEcCtD
Dasatinib—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.000136	0.000464	CcSEcCtD
Dasatinib—Dizziness—Raloxifene—osteoporosis	0.000136	0.000464	CcSEcCtD
Dasatinib—Hyperhidrosis—Conjugated Estrogens—osteoporosis	0.000135	0.000463	CcSEcCtD
Dasatinib—Vomiting—Estropipate—osteoporosis	0.000135	0.00046	CcSEcCtD
Dasatinib—Dysgeusia—Estradiol—osteoporosis	0.000134	0.00046	CcSEcCtD
Dasatinib—Dizziness—Ibandronate—osteoporosis	0.000134	0.000459	CcSEcCtD
Dasatinib—Rash—Estropipate—osteoporosis	0.000134	0.000457	CcSEcCtD
Dasatinib—Dermatitis—Estropipate—osteoporosis	0.000134	0.000456	CcSEcCtD
Dasatinib—Anorexia—Conjugated Estrogens—osteoporosis	0.000133	0.000456	CcSEcCtD
Dasatinib—Urticaria—Risedronate—osteoporosis	0.000133	0.000455	CcSEcCtD
Dasatinib—Headache—Estropipate—osteoporosis	0.000133	0.000454	CcSEcCtD
Dasatinib—Vomiting—Alendronate—osteoporosis	0.000133	0.000454	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Zoledronate—osteoporosis	0.000133	0.000453	CcSEcCtD
Dasatinib—Body temperature increased—Risedronate—osteoporosis	0.000132	0.000452	CcSEcCtD
Dasatinib—Abdominal pain—Risedronate—osteoporosis	0.000132	0.000452	CcSEcCtD
Dasatinib—Muscle spasms—Estradiol—osteoporosis	0.000132	0.000451	CcSEcCtD
Dasatinib—Rash—Alendronate—osteoporosis	0.000132	0.00045	CcSEcCtD
Dasatinib—Insomnia—Zoledronate—osteoporosis	0.000132	0.000449	CcSEcCtD
Dasatinib—Dermatitis—Alendronate—osteoporosis	0.000131	0.000449	CcSEcCtD
Dasatinib—Feeling abnormal—Pamidronate—osteoporosis	0.000131	0.000448	CcSEcCtD
Dasatinib—Hypotension—Conjugated Estrogens—osteoporosis	0.000131	0.000447	CcSEcCtD
Dasatinib—Headache—Alendronate—osteoporosis	0.000131	0.000447	CcSEcCtD
Dasatinib—Vomiting—Raloxifene—osteoporosis	0.000131	0.000446	CcSEcCtD
Dasatinib—Gastrointestinal pain—Pamidronate—osteoporosis	0.00013	0.000445	CcSEcCtD
Dasatinib—Dyspnoea—Zoledronate—osteoporosis	0.00013	0.000443	CcSEcCtD
Dasatinib—Rash—Raloxifene—osteoporosis	0.000129	0.000442	CcSEcCtD
Dasatinib—Dermatitis—Raloxifene—osteoporosis	0.000129	0.000442	CcSEcCtD
Dasatinib—Somnolence—Zoledronate—osteoporosis	0.000129	0.000442	CcSEcCtD
Dasatinib—Vomiting—Ibandronate—osteoporosis	0.000129	0.000442	CcSEcCtD
Dasatinib—Tremor—Estradiol—osteoporosis	0.000129	0.00044	CcSEcCtD
Dasatinib—Headache—Raloxifene—osteoporosis	0.000129	0.000439	CcSEcCtD
Dasatinib—Rash—Ibandronate—osteoporosis	0.000128	0.000438	CcSEcCtD
Dasatinib—Dermatitis—Ibandronate—osteoporosis	0.000128	0.000437	CcSEcCtD
Dasatinib—Dyspepsia—Zoledronate—osteoporosis	0.000128	0.000437	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	0.000128	0.000436	CcSEcCtD
Dasatinib—Ill-defined disorder—Estradiol—osteoporosis	0.000127	0.000435	CcSEcCtD
Dasatinib—Headache—Ibandronate—osteoporosis	0.000127	0.000435	CcSEcCtD
Dasatinib—Insomnia—Conjugated Estrogens—osteoporosis	0.000127	0.000433	CcSEcCtD
Dasatinib—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.000127	0.000432	CcSEcCtD
Dasatinib—Vomiting—Calcitriol—osteoporosis	0.000126	0.000432	CcSEcCtD
Dasatinib—Decreased appetite—Zoledronate—osteoporosis	0.000126	0.000432	CcSEcCtD
Dasatinib—Nausea—Estropipate—osteoporosis	0.000126	0.00043	CcSEcCtD
Dasatinib—Body temperature increased—Pamidronate—osteoporosis	0.000126	0.00043	CcSEcCtD
Dasatinib—Abdominal pain—Pamidronate—osteoporosis	0.000126	0.00043	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Zoledronate—osteoporosis	0.000126	0.000429	CcSEcCtD
Dasatinib—Rash—Calcitriol—osteoporosis	0.000125	0.000429	CcSEcCtD
Dasatinib—Fatigue—Zoledronate—osteoporosis	0.000125	0.000428	CcSEcCtD
Dasatinib—Dermatitis—Calcitriol—osteoporosis	0.000125	0.000428	CcSEcCtD
Dasatinib—Dyspnoea—Conjugated Estrogens—osteoporosis	0.000125	0.000427	CcSEcCtD
Dasatinib—Headache—Calcitriol—osteoporosis	0.000125	0.000426	CcSEcCtD
Dasatinib—Somnolence—Conjugated Estrogens—osteoporosis	0.000124	0.000425	CcSEcCtD
Dasatinib—Pain—Zoledronate—osteoporosis	0.000124	0.000425	CcSEcCtD
Dasatinib—Constipation—Zoledronate—osteoporosis	0.000124	0.000425	CcSEcCtD
Dasatinib—Nausea—Alendronate—osteoporosis	0.000124	0.000424	CcSEcCtD
Dasatinib—Malaise—Estradiol—osteoporosis	0.000124	0.000423	CcSEcCtD
Dasatinib—Hypersensitivity—Risedronate—osteoporosis	0.000123	0.000422	CcSEcCtD
Dasatinib—Vertigo—Estradiol—osteoporosis	0.000123	0.000422	CcSEcCtD
Dasatinib—Dyspepsia—Conjugated Estrogens—osteoporosis	0.000123	0.000421	CcSEcCtD
Dasatinib—Asthenia—Ethinyl Estradiol—osteoporosis	0.000123	0.000421	CcSEcCtD
Dasatinib—Syncope—Estradiol—osteoporosis	0.000123	0.000421	CcSEcCtD
Dasatinib—Nausea—Raloxifene—osteoporosis	0.000122	0.000417	CcSEcCtD
Dasatinib—Decreased appetite—Conjugated Estrogens—osteoporosis	0.000122	0.000416	CcSEcCtD
Dasatinib—Pruritus—Ethinyl Estradiol—osteoporosis	0.000122	0.000415	CcSEcCtD
Dasatinib—Palpitations—Estradiol—osteoporosis	0.000121	0.000415	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000121	0.000413	CcSEcCtD
Dasatinib—Fatigue—Conjugated Estrogens—osteoporosis	0.000121	0.000413	CcSEcCtD
Dasatinib—Nausea—Ibandronate—osteoporosis	0.000121	0.000413	CcSEcCtD
Dasatinib—Loss of consciousness—Estradiol—osteoporosis	0.000121	0.000412	CcSEcCtD
Dasatinib—Asthenia—Risedronate—osteoporosis	0.00012	0.000411	CcSEcCtD
Dasatinib—Feeling abnormal—Zoledronate—osteoporosis	0.00012	0.00041	CcSEcCtD
Dasatinib—Cough—Estradiol—osteoporosis	0.00012	0.000409	CcSEcCtD
Dasatinib—Pain—Conjugated Estrogens—osteoporosis	0.00012	0.000409	CcSEcCtD
Dasatinib—Constipation—Conjugated Estrogens—osteoporosis	0.00012	0.000409	CcSEcCtD
Dasatinib—Gastrointestinal pain—Zoledronate—osteoporosis	0.000119	0.000406	CcSEcCtD
Dasatinib—Hypertension—Estradiol—osteoporosis	0.000119	0.000405	CcSEcCtD
Dasatinib—Pruritus—Risedronate—osteoporosis	0.000119	0.000405	CcSEcCtD
Dasatinib—Nausea—Calcitriol—osteoporosis	0.000118	0.000404	CcSEcCtD
Dasatinib—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000118	0.000402	CcSEcCtD
Dasatinib—Hypersensitivity—Pamidronate—osteoporosis	0.000117	0.000401	CcSEcCtD
Dasatinib—Arthralgia—Estradiol—osteoporosis	0.000117	0.0004	CcSEcCtD
Dasatinib—Myalgia—Estradiol—osteoporosis	0.000117	0.0004	CcSEcCtD
Dasatinib—Chest pain—Estradiol—osteoporosis	0.000117	0.0004	CcSEcCtD
Dasatinib—Anxiety—Estradiol—osteoporosis	0.000117	0.000398	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.000116	0.000397	CcSEcCtD
Dasatinib—Urticaria—Zoledronate—osteoporosis	0.000116	0.000395	CcSEcCtD
Dasatinib—Discomfort—Estradiol—osteoporosis	0.000116	0.000395	CcSEcCtD
Dasatinib—Abdominal pain—Zoledronate—osteoporosis	0.000115	0.000393	CcSEcCtD
Dasatinib—Body temperature increased—Zoledronate—osteoporosis	0.000115	0.000393	CcSEcCtD
Dasatinib—Diarrhoea—Risedronate—osteoporosis	0.000115	0.000392	CcSEcCtD
Dasatinib—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	0.000115	0.000391	CcSEcCtD
Dasatinib—Asthenia—Pamidronate—osteoporosis	0.000114	0.00039	CcSEcCtD
Dasatinib—Dizziness—Ethinyl Estradiol—osteoporosis	0.000114	0.000388	CcSEcCtD
Dasatinib—Confusional state—Estradiol—osteoporosis	0.000113	0.000386	CcSEcCtD
Dasatinib—Pruritus—Pamidronate—osteoporosis	0.000113	0.000385	CcSEcCtD
Dasatinib—Oedema—Estradiol—osteoporosis	0.000112	0.000383	CcSEcCtD
Dasatinib—Infection—Estradiol—osteoporosis	0.000111	0.00038	CcSEcCtD
Dasatinib—Urticaria—Conjugated Estrogens—osteoporosis	0.000111	0.00038	CcSEcCtD
Dasatinib—Dizziness—Risedronate—osteoporosis	0.000111	0.000378	CcSEcCtD
Dasatinib—Abdominal pain—Conjugated Estrogens—osteoporosis	0.000111	0.000378	CcSEcCtD
Dasatinib—Body temperature increased—Conjugated Estrogens—osteoporosis	0.000111	0.000378	CcSEcCtD
Dasatinib—Shock—Estradiol—osteoporosis	0.00011	0.000377	CcSEcCtD
Dasatinib—Nervous system disorder—Estradiol—osteoporosis	0.00011	0.000376	CcSEcCtD
Dasatinib—Tachycardia—Estradiol—osteoporosis	0.000109	0.000374	CcSEcCtD
Dasatinib—Vomiting—Ethinyl Estradiol—osteoporosis	0.000109	0.000373	CcSEcCtD
Dasatinib—Diarrhoea—Pamidronate—osteoporosis	0.000109	0.000372	CcSEcCtD
Dasatinib—Skin disorder—Estradiol—osteoporosis	0.000109	0.000372	CcSEcCtD
Dasatinib—Hyperhidrosis—Estradiol—osteoporosis	0.000108	0.00037	CcSEcCtD
Dasatinib—Rash—Ethinyl Estradiol—osteoporosis	0.000108	0.00037	CcSEcCtD
Dasatinib—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000108	0.00037	CcSEcCtD
Dasatinib—Headache—Ethinyl Estradiol—osteoporosis	0.000108	0.000368	CcSEcCtD
Dasatinib—Hypersensitivity—Zoledronate—osteoporosis	0.000107	0.000366	CcSEcCtD
Dasatinib—Vomiting—Risedronate—osteoporosis	0.000106	0.000364	CcSEcCtD
Dasatinib—Rash—Risedronate—osteoporosis	0.000106	0.000361	CcSEcCtD
Dasatinib—Dermatitis—Risedronate—osteoporosis	0.000106	0.000361	CcSEcCtD
Dasatinib—Dizziness—Pamidronate—osteoporosis	0.000105	0.00036	CcSEcCtD
Dasatinib—Headache—Risedronate—osteoporosis	0.000105	0.000359	CcSEcCtD
Dasatinib—Asthenia—Zoledronate—osteoporosis	0.000104	0.000357	CcSEcCtD
Dasatinib—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000103	0.000353	CcSEcCtD
Dasatinib—Pruritus—Zoledronate—osteoporosis	0.000103	0.000352	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Estradiol—osteoporosis	0.000102	0.000349	CcSEcCtD
Dasatinib—Nausea—Ethinyl Estradiol—osteoporosis	0.000102	0.000349	CcSEcCtD
Dasatinib—Insomnia—Estradiol—osteoporosis	0.000101	0.000346	CcSEcCtD
Dasatinib—Vomiting—Pamidronate—osteoporosis	0.000101	0.000346	CcSEcCtD
Dasatinib—Asthenia—Conjugated Estrogens—osteoporosis	0.0001	0.000343	CcSEcCtD
Dasatinib—Rash—Pamidronate—osteoporosis	0.0001	0.000343	CcSEcCtD
Dasatinib—Dermatitis—Pamidronate—osteoporosis	0.0001	0.000343	CcSEcCtD
Dasatinib—Dyspnoea—Estradiol—osteoporosis	9.99e-05	0.000341	CcSEcCtD
Dasatinib—Headache—Pamidronate—osteoporosis	9.97e-05	0.000341	CcSEcCtD
Dasatinib—Somnolence—Estradiol—osteoporosis	9.96e-05	0.00034	CcSEcCtD
Dasatinib—Diarrhoea—Zoledronate—osteoporosis	9.95e-05	0.00034	CcSEcCtD
Dasatinib—Nausea—Risedronate—osteoporosis	9.95e-05	0.00034	CcSEcCtD
Dasatinib—Pruritus—Conjugated Estrogens—osteoporosis	9.91e-05	0.000339	CcSEcCtD
Dasatinib—Dyspepsia—Estradiol—osteoporosis	9.87e-05	0.000337	CcSEcCtD
Dasatinib—Decreased appetite—Estradiol—osteoporosis	9.74e-05	0.000333	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Estradiol—osteoporosis	9.68e-05	0.000331	CcSEcCtD
Dasatinib—Fatigue—Estradiol—osteoporosis	9.66e-05	0.00033	CcSEcCtD
Dasatinib—Dizziness—Zoledronate—osteoporosis	9.62e-05	0.000329	CcSEcCtD
Dasatinib—Constipation—Estradiol—osteoporosis	9.58e-05	0.000327	CcSEcCtD
Dasatinib—Pain—Estradiol—osteoporosis	9.58e-05	0.000327	CcSEcCtD
Dasatinib—Diarrhoea—Conjugated Estrogens—osteoporosis	9.58e-05	0.000327	CcSEcCtD
Dasatinib—Nausea—Pamidronate—osteoporosis	9.46e-05	0.000323	CcSEcCtD
Dasatinib—Dizziness—Conjugated Estrogens—osteoporosis	9.26e-05	0.000316	CcSEcCtD
Dasatinib—Vomiting—Zoledronate—osteoporosis	9.25e-05	0.000316	CcSEcCtD
Dasatinib—Feeling abnormal—Estradiol—osteoporosis	9.24e-05	0.000316	CcSEcCtD
Dasatinib—Rash—Zoledronate—osteoporosis	9.17e-05	0.000313	CcSEcCtD
Dasatinib—Gastrointestinal pain—Estradiol—osteoporosis	9.17e-05	0.000313	CcSEcCtD
Dasatinib—Dermatitis—Zoledronate—osteoporosis	9.16e-05	0.000313	CcSEcCtD
Dasatinib—Headache—Zoledronate—osteoporosis	9.11e-05	0.000311	CcSEcCtD
Dasatinib—Vomiting—Conjugated Estrogens—osteoporosis	8.9e-05	0.000304	CcSEcCtD
Dasatinib—Urticaria—Estradiol—osteoporosis	8.9e-05	0.000304	CcSEcCtD
Dasatinib—Abdominal pain—Estradiol—osteoporosis	8.86e-05	0.000303	CcSEcCtD
Dasatinib—Body temperature increased—Estradiol—osteoporosis	8.86e-05	0.000303	CcSEcCtD
Dasatinib—Rash—Conjugated Estrogens—osteoporosis	8.83e-05	0.000302	CcSEcCtD
Dasatinib—Dermatitis—Conjugated Estrogens—osteoporosis	8.82e-05	0.000301	CcSEcCtD
Dasatinib—Headache—Conjugated Estrogens—osteoporosis	8.77e-05	0.0003	CcSEcCtD
Dasatinib—Nausea—Zoledronate—osteoporosis	8.64e-05	0.000295	CcSEcCtD
Dasatinib—Nausea—Conjugated Estrogens—osteoporosis	8.32e-05	0.000284	CcSEcCtD
Dasatinib—Hypersensitivity—Estradiol—osteoporosis	8.26e-05	0.000282	CcSEcCtD
Dasatinib—Asthenia—Estradiol—osteoporosis	8.04e-05	0.000275	CcSEcCtD
Dasatinib—Pruritus—Estradiol—osteoporosis	7.93e-05	0.000271	CcSEcCtD
Dasatinib—Diarrhoea—Estradiol—osteoporosis	7.67e-05	0.000262	CcSEcCtD
Dasatinib—Dizziness—Estradiol—osteoporosis	7.41e-05	0.000253	CcSEcCtD
Dasatinib—Vomiting—Estradiol—osteoporosis	7.13e-05	0.000244	CcSEcCtD
Dasatinib—Rash—Estradiol—osteoporosis	7.07e-05	0.000241	CcSEcCtD
Dasatinib—Dermatitis—Estradiol—osteoporosis	7.06e-05	0.000241	CcSEcCtD
Dasatinib—Headache—Estradiol—osteoporosis	7.02e-05	0.00024	CcSEcCtD
Dasatinib—Nausea—Estradiol—osteoporosis	6.66e-05	0.000227	CcSEcCtD
Dasatinib—LYN—Signaling Pathways—SPP1—osteoporosis	4.19e-06	1.46e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—IL6R—osteoporosis	4.17e-06	1.46e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Innate Immune System—IL6—osteoporosis	4.17e-06	1.46e-05	CbGpPWpGaD
Dasatinib—LYN—Developmental Biology—IL6—osteoporosis	4.16e-06	1.45e-05	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—MTHFR—osteoporosis	4.16e-06	1.45e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—IL6R—osteoporosis	4.15e-06	1.45e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—IL1B—osteoporosis	4.14e-06	1.45e-05	CbGpPWpGaD
Dasatinib—ABL1—Developmental Biology—IL6—osteoporosis	4.14e-06	1.45e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—CYP27A1—osteoporosis	4.14e-06	1.44e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—MTHFR—osteoporosis	4.13e-06	1.44e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—SPP1—osteoporosis	4.12e-06	1.44e-05	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—ADCY5—osteoporosis	4.11e-06	1.44e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—IGF1—osteoporosis	4.11e-06	1.44e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—ADCY5—osteoporosis	4.11e-06	1.43e-05	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—GPX1—osteoporosis	4.1e-06	1.43e-05	CbGpPWpGaD
Dasatinib—FYN—Developmental Biology—IL6—osteoporosis	4.1e-06	1.43e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—OXCT1—osteoporosis	4.1e-06	1.43e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CA2—osteoporosis	4.1e-06	1.43e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—ADCY5—osteoporosis	4.05e-06	1.42e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—ACP5—osteoporosis	4.02e-06	1.41e-05	CbGpPWpGaD
Dasatinib—ERBB3—Disease—MYC—osteoporosis	4.02e-06	1.4e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—ESR1—osteoporosis	4.01e-06	1.4e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—KL—osteoporosis	4.01e-06	1.4e-05	CbGpPWpGaD
Dasatinib—SRC—Developmental Biology—TGFB1—osteoporosis	4.01e-06	1.4e-05	CbGpPWpGaD
Dasatinib—ERBB3—Disease—TGFB1—osteoporosis	4.01e-06	1.4e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—MGLL—osteoporosis	3.99e-06	1.39e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	3.97e-06	1.39e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—SPP1—osteoporosis	3.97e-06	1.39e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—IRS1—osteoporosis	3.96e-06	1.38e-05	CbGpPWpGaD
Dasatinib—MAPK14—Developmental Biology—IL6—osteoporosis	3.95e-06	1.38e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—IL6R—osteoporosis	3.94e-06	1.38e-05	CbGpPWpGaD
Dasatinib—HCK—Immune System—IL6—osteoporosis	3.94e-06	1.38e-05	CbGpPWpGaD
Dasatinib—SRC—Hemostasis—TGFB1—osteoporosis	3.93e-06	1.37e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—IRS2—osteoporosis	3.93e-06	1.37e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—SPP1—osteoporosis	3.92e-06	1.37e-05	CbGpPWpGaD
Dasatinib—JAK2—Developmental Biology—IL6—osteoporosis	3.89e-06	1.36e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—IRS1—osteoporosis	3.87e-06	1.35e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—IRS2—osteoporosis	3.87e-06	1.35e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—POMC—osteoporosis	3.81e-06	1.33e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—IRS2—osteoporosis	3.79e-06	1.32e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—LEP—osteoporosis	3.79e-06	1.32e-05	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—MTHFR—osteoporosis	3.78e-06	1.32e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Innate Immune System—IL6—osteoporosis	3.75e-06	1.31e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—IRS1—osteoporosis	3.75e-06	1.31e-05	CbGpPWpGaD
Dasatinib—SRC—Developmental Biology—TNF—osteoporosis	3.74e-06	1.31e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—TPI1—osteoporosis	3.74e-06	1.31e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—IL1B—osteoporosis	3.73e-06	1.3e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—IRS2—osteoporosis	3.73e-06	1.3e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—IL6R—osteoporosis	3.72e-06	1.3e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—IRS1—osteoporosis	3.71e-06	1.3e-05	CbGpPWpGaD
Dasatinib—RIPK2—Immune System—IL6—osteoporosis	3.71e-06	1.3e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—LEP—osteoporosis	3.71e-06	1.3e-05	CbGpPWpGaD
Dasatinib—LYN—Innate Immune System—IL6—osteoporosis	3.68e-06	1.28e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—IGF1—osteoporosis	3.67e-06	1.28e-05	CbGpPWpGaD
Dasatinib—ABL1—Innate Immune System—IL6—osteoporosis	3.66e-06	1.28e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—IL1B—osteoporosis	3.66e-06	1.28e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—LEP—osteoporosis	3.65e-06	1.28e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—IL1B—osteoporosis	3.64e-06	1.27e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—IL6R—osteoporosis	3.64e-06	1.27e-05	CbGpPWpGaD
Dasatinib—HCK—Disease—IL6—osteoporosis	3.64e-06	1.27e-05	CbGpPWpGaD
Dasatinib—FYN—Innate Immune System—IL6—osteoporosis	3.62e-06	1.26e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—ESR1—osteoporosis	3.62e-06	1.26e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—POMC—osteoporosis	3.61e-06	1.26e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—CYP19A1—osteoporosis	3.61e-06	1.26e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—IL1B—osteoporosis	3.6e-06	1.26e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—IRS2—osteoporosis	3.59e-06	1.25e-05	CbGpPWpGaD
Dasatinib—BLK—Immune System—IL6—osteoporosis	3.57e-06	1.25e-05	CbGpPWpGaD
Dasatinib—FGR—Immune System—IL6—osteoporosis	3.56e-06	1.24e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—ADCY5—osteoporosis	3.55e-06	1.24e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—IRS2—osteoporosis	3.55e-06	1.24e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—ESR1—osteoporosis	3.54e-06	1.24e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—IL6R—osteoporosis	3.52e-06	1.23e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—P4HB—osteoporosis	3.52e-06	1.23e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—LEP—osteoporosis	3.51e-06	1.23e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—IL6R—osteoporosis	3.49e-06	1.22e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—ESR1—osteoporosis	3.48e-06	1.22e-05	CbGpPWpGaD
Dasatinib—MAPK14—Innate Immune System—IL6—osteoporosis	3.48e-06	1.22e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—IGF1—osteoporosis	3.47e-06	1.21e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—LEP—osteoporosis	3.47e-06	1.21e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—IL1B—osteoporosis	3.47e-06	1.21e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—GAPDH—osteoporosis	3.45e-06	1.21e-05	CbGpPWpGaD
Dasatinib—JAK2—Innate Immune System—IL6—osteoporosis	3.44e-06	1.2e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—SPP1—osteoporosis	3.43e-06	1.2e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—IRS1—osteoporosis	3.43e-06	1.2e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—IL1B—osteoporosis	3.42e-06	1.2e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—CYP19A1—osteoporosis	3.41e-06	1.19e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—ENO1—osteoporosis	3.4e-06	1.19e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—IDH2—osteoporosis	3.39e-06	1.19e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—IRS1—osteoporosis	3.38e-06	1.18e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—RAP1A—osteoporosis	3.36e-06	1.17e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—ESR1—osteoporosis	3.36e-06	1.17e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PSMA2—osteoporosis	3.35e-06	1.17e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PSMA5—osteoporosis	3.35e-06	1.17e-05	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—POMC—osteoporosis	3.32e-06	1.16e-05	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—IL6—osteoporosis	3.32e-06	1.16e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—ESR1—osteoporosis	3.31e-06	1.16e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—IRS1—osteoporosis	3.31e-06	1.16e-05	CbGpPWpGaD
Dasatinib—ERBB3—Immune System—IL6—osteoporosis	3.27e-06	1.14e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—IRS1—osteoporosis	3.26e-06	1.14e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—POMC—osteoporosis	3.25e-06	1.14e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—IL6R—osteoporosis	3.22e-06	1.12e-05	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—IL6—osteoporosis	3.21e-06	1.12e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CYP27A1—osteoporosis	3.19e-06	1.11e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—MYC—osteoporosis	3.19e-06	1.11e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—POMC—osteoporosis	3.19e-06	1.11e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—TGFB1—osteoporosis	3.18e-06	1.11e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—IL6R—osteoporosis	3.17e-06	1.11e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—MYC—osteoporosis	3.15e-06	1.1e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—ADCY5—osteoporosis	3.14e-06	1.1e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—TGFB1—osteoporosis	3.14e-06	1.1e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—POMC—osteoporosis	3.14e-06	1.1e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—IRS1—osteoporosis	3.14e-06	1.1e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—IGF1—osteoporosis	3.13e-06	1.09e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—IL6R—osteoporosis	3.11e-06	1.09e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—IRS2—osteoporosis	3.11e-06	1.08e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—ACP5—osteoporosis	3.1e-06	1.08e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—IRS1—osteoporosis	3.1e-06	1.08e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—IGF1—osteoporosis	3.06e-06	1.07e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—IL6R—osteoporosis	3.06e-06	1.07e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—SPP1—osteoporosis	3.04e-06	1.06e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—LEP—osteoporosis	3.04e-06	1.06e-05	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—POMC—osteoporosis	3.02e-06	1.06e-05	CbGpPWpGaD
Dasatinib—SRC—Developmental Biology—IL6—osteoporosis	3.02e-06	1.06e-05	CbGpPWpGaD
Dasatinib—ERBB3—Disease—IL6—osteoporosis	3.02e-06	1.05e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—POMC—osteoporosis	3.02e-06	1.05e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—IGF1—osteoporosis	3.02e-06	1.05e-05	CbGpPWpGaD
Dasatinib—LCK—Innate Immune System—IL6—osteoporosis	3.01e-06	1.05e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—IL1B—osteoporosis	3e-06	1.05e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—MYC—osteoporosis	2.98e-06	1.04e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—POMC—osteoporosis	2.98e-06	1.04e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—TGFB1—osteoporosis	2.97e-06	1.04e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—ADCY5—osteoporosis	2.95e-06	1.03e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—IL6R—osteoporosis	2.95e-06	1.03e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—GPX1—osteoporosis	2.94e-06	1.03e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—POMC—osteoporosis	2.93e-06	1.02e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—MYC—osteoporosis	2.92e-06	1.02e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—TGFB1—osteoporosis	2.91e-06	1.02e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—IL6R—osteoporosis	2.91e-06	1.02e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—IGF1—osteoporosis	2.9e-06	1.01e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—ESR1—osteoporosis	2.9e-06	1.01e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—TPI1—osteoporosis	2.89e-06	1.01e-05	CbGpPWpGaD
Dasatinib—YES1—Immune System—IL6—osteoporosis	2.87e-06	1e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—IGF1—osteoporosis	2.87e-06	1e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—MYC—osteoporosis	2.81e-06	9.83e-06	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—TGFB1—osteoporosis	2.81e-06	9.8e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—ADCY5—osteoporosis	2.78e-06	9.72e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—GPX1—osteoporosis	2.77e-06	9.69e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—IRS2—osteoporosis	2.75e-06	9.6e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—CYP19A1—osteoporosis	2.72e-06	9.51e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—ENO1—osteoporosis	2.72e-06	9.49e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—P4HB—osteoporosis	2.71e-06	9.48e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—IRS1—osteoporosis	2.71e-06	9.47e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—MTHFR—osteoporosis	2.71e-06	9.47e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—LEP—osteoporosis	2.69e-06	9.4e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—MYC—osteoporosis	2.69e-06	9.38e-06	CbGpPWpGaD
Dasatinib—MAPK14—Gene Expression—MYC—osteoporosis	2.68e-06	9.38e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—TGFB1—osteoporosis	2.68e-06	9.36e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PSMA2—osteoporosis	2.68e-06	9.35e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PSMA5—osteoporosis	2.68e-06	9.35e-06	CbGpPWpGaD
Dasatinib—SRC—Innate Immune System—IL6—osteoporosis	2.67e-06	9.32e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GAPDH—osteoporosis	2.66e-06	9.31e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—IL1B—osteoporosis	2.65e-06	9.27e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—POMC—osteoporosis	2.61e-06	9.12e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—RAP1A—osteoporosis	2.59e-06	9.06e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—MYC—osteoporosis	2.59e-06	9.04e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—TGFB1—osteoporosis	2.58e-06	9.02e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—ESR1—osteoporosis	2.57e-06	8.97e-06	CbGpPWpGaD
Dasatinib—KIT—Immune System—IL6—osteoporosis	2.56e-06	8.96e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—MTHFR—osteoporosis	2.56e-06	8.94e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—IL6R—osteoporosis	2.55e-06	8.9e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—IGF1—osteoporosis	2.51e-06	8.77e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—MYC—osteoporosis	2.47e-06	8.63e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—TGFB1—osteoporosis	2.46e-06	8.61e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—MYC—osteoporosis	2.46e-06	8.6e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—TGFB1—osteoporosis	2.45e-06	8.58e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—IL6—osteoporosis	2.43e-06	8.48e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—IRS1—osteoporosis	2.4e-06	8.38e-06	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—IL6—osteoporosis	2.4e-06	8.38e-06	CbGpPWpGaD
Dasatinib—KIT—Disease—IL6—osteoporosis	2.37e-06	8.27e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—POMC—osteoporosis	2.31e-06	8.07e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—IL6R—osteoporosis	2.25e-06	7.88e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—IL6—osteoporosis	2.24e-06	7.83e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—ADCY5—osteoporosis	2.22e-06	7.77e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—IGF1—osteoporosis	2.22e-06	7.77e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—GPX1—osteoporosis	2.22e-06	7.74e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—MYC—osteoporosis	2.21e-06	7.7e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—TGFB1—osteoporosis	2.2e-06	7.69e-06	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—IL6—osteoporosis	2.19e-06	7.66e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—IL6—osteoporosis	2.19e-06	7.66e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—IL6—osteoporosis	2.19e-06	7.64e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—CYP19A1—osteoporosis	2.17e-06	7.59e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—POMC—osteoporosis	2.17e-06	7.57e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—MYC—osteoporosis	2.16e-06	7.53e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—TGFB1—osteoporosis	2.15e-06	7.51e-06	CbGpPWpGaD
Dasatinib—LYN—Immune System—IL6—osteoporosis	2.14e-06	7.48e-06	CbGpPWpGaD
Dasatinib—ABL1—Immune System—IL6—osteoporosis	2.13e-06	7.44e-06	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—IL6—osteoporosis	2.11e-06	7.39e-06	CbGpPWpGaD
Dasatinib—FYN—Immune System—IL6—osteoporosis	2.11e-06	7.36e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—ENO1—osteoporosis	2.1e-06	7.33e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—MYC—osteoporosis	2.09e-06	7.29e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—TGFB1—osteoporosis	2.08e-06	7.27e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PSMA2—osteoporosis	2.07e-06	7.22e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PSMA5—osteoporosis	2.07e-06	7.22e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—POMC—osteoporosis	2.05e-06	7.15e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—MTHFR—osteoporosis	2.04e-06	7.14e-06	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—IL6—osteoporosis	2.03e-06	7.09e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—IL6—osteoporosis	2.02e-06	7.05e-06	CbGpPWpGaD
Dasatinib—JAK2—Immune System—IL6—osteoporosis	2e-06	7e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—IL6—osteoporosis	1.95e-06	6.8e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—MYC—osteoporosis	1.91e-06	6.67e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—TGFB1—osteoporosis	1.9e-06	6.65e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—MYC—osteoporosis	1.88e-06	6.57e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—TGFB1—osteoporosis	1.88e-06	6.55e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—IL6—osteoporosis	1.86e-06	6.48e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—IL6—osteoporosis	1.85e-06	6.46e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—MYC—osteoporosis	1.84e-06	6.43e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—TGFB1—osteoporosis	1.84e-06	6.42e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—MYC—osteoporosis	1.81e-06	6.33e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—TGFB1—osteoporosis	1.81e-06	6.32e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—ADCY5—osteoporosis	1.77e-06	6.2e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—GPX1—osteoporosis	1.77e-06	6.18e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—IL6—osteoporosis	1.75e-06	6.13e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—MYC—osteoporosis	1.75e-06	6.1e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—TGFB1—osteoporosis	1.74e-06	6.08e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—MYC—osteoporosis	1.72e-06	6.02e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—TGFB1—osteoporosis	1.72e-06	6.01e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CYP19A1—osteoporosis	1.68e-06	5.86e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—IL6—osteoporosis	1.66e-06	5.79e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—POMC—osteoporosis	1.64e-06	5.71e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—MTHFR—osteoporosis	1.63e-06	5.7e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—IL6—osteoporosis	1.62e-06	5.66e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—IL6—osteoporosis	1.57e-06	5.48e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—IL6—osteoporosis	1.55e-06	5.43e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MYC—osteoporosis	1.51e-06	5.27e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—TGFB1—osteoporosis	1.51e-06	5.26e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—IL6—osteoporosis	1.43e-06	5.01e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—IL6—osteoporosis	1.41e-06	4.94e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—IL6—osteoporosis	1.38e-06	4.84e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—ADCY5—osteoporosis	1.37e-06	4.79e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GPX1—osteoporosis	1.37e-06	4.77e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—IL6—osteoporosis	1.36e-06	4.76e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MYC—osteoporosis	1.34e-06	4.67e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—TGFB1—osteoporosis	1.33e-06	4.66e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—IL6—osteoporosis	1.31e-06	4.58e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—POMC—osteoporosis	1.31e-06	4.56e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—IL6—osteoporosis	1.3e-06	4.53e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—MTHFR—osteoporosis	1.26e-06	4.4e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—IL6—osteoporosis	1.13e-06	3.96e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—POMC—osteoporosis	1.01e-06	3.52e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—IL6—osteoporosis	1e-06	3.51e-06	CbGpPWpGaD
